Global Multiple Sclerosis Drugs Market Size, Share, Growth Analysis, By Drug Type(Immunomodulatory, Immunosuppressant), By Route of Administration(Oral and Parenteral)

Description

Global Multiple Sclerosis Drugs Market size was valued at USD 24.64 Billion in 2022 and is poised to grow from USD 25.40 Billion in 2023 to USD 32.43 Billion by 2031, at a CAGR of 3.10% during the forecast period (2024-2031).

Due to factors such as the rising occurrence of multiple sclerosis (MS), the market in focus is expected to witness rapid growth in the future. According to a study published in December 2020 titled "Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition," it is estimated that approximately 2.8 million individuals (equating to 35.9 per 100,000 people) worldwide are believed to be affected by MS. The prevalence of MS has shown a global increase, although there are still gaps in the estimates of prevalence. Across all 75 reporting nations, the combined incidence rate stands at 2.1 per 100,000 people annually, with an average age of diagnosis being 32. Additionally, females are twice as likely as males to be diagnosed with MS.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Sclerosis Drugs Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Global Multiple Sclerosis Drugs Market Segmental Analysis

Global Multiple Sclerosis Drugs Market is segmented on the basis of Drug Type, Route of Administration and region. By Drug Type, the market is segmented into Immunomodulatory, Immunosuppressant, Interferons, Corticosteroids. By Route of Administration, market is segmented into Oral and Parenteral. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Multiple Sclerosis Drugs Market

Drugs currently utilized in multiple sclerosis treatment are frequently subjected to further testing for additional uses and expanded indications. For instance, certain medications initially sanctioned for relapsing-remitting MS have subsequently obtained approvals for secondary progressive MS or clinically isolated syndrome. These expanded indications broaden the range of patients who can potentially benefit from these drugs, thereby resulting in heightened sales and market expansion.

In numerous countries, governments and insurance firms have instituted favourable reimbursement policies for drugs used in treating multiple sclerosis (MS). These policies are designed to enhance patient access to medications by alleviating financial burdens. By providing reimbursement support, more patients can afford costly MS drugs, thereby stimulating market growth.

Restraints in the Global Multiple Sclerosis Drugs Market

MS medications, particularly the newer disease-modifying therapies, are frequently linked with considerable expenses. These costs can impose significant financial challenges on patients, healthcare systems, and payers alike. The restricted affordability and access to expensive MS drugs may hinder their uptake and constrain market expansion, particularly in areas with constrained healthcare budgets or insufficient insurance coverage.

Market Trends of the Global Multiple Sclerosis Drugs Market

The advancement of disease-modifying therapies (DMTs) is pivotal in the management of MS, as they serve to decrease relapse rates, postpone disease advancement, and safeguard neurological function. The market has seen the emergence of novel and enhanced DMTs, including monoclonal antibodies and oral treatments, which offer improved efficacy and safety attributes. The emphasis on enhancing DMTs remains a driving force in the market, offering patients a broader array of choices for managing the disease.

Product Code: SQMIG35I2199

Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
  - Drivers
  - Opportunities
  - Restraints
  - Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
  - Drivers
  - Opportunities
  - Restraints
  - Challenges
- Regulatory Landscape
- Porters Analysis
  - Competitive rivalry
  - Threat of Substitute Products
  - Bargaining Power of Buyers
  - Threat of New Entrants
  - Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
  - Political Impact
  - Economic Impact
  - Social Impact
  - Technical Impact
  - Environmental Impact
  - Legal Impact
Global Multiple Sclerosis Drugs Market by Drug Type
- Market Overview
- Immunomodulatory
- Immunosuppressant
- Interferons
- Corticosteroids
Global Multiple Sclerosis Drugs Market by Route of Administration
- Market Overview
- Oral and Parenteral
Global Multiple Sclerosis Drugs Market Size by Region
- Market Overview
- North America
  - USA
  - Canada
- Europe
  - Germany
  - Spain
  - France
  - UK
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - South Korea
  - Rest of Asia-Pacific
- Latin America
  - Brazil
  - Rest of Latin America
- Middle East & Africa (MEA)
  - GCC Countries
  - South Africa
  - Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
  - By Development
  - By Company
  - By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Biogen Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Roche Holdings AG (Switzerland)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Novartis AG (Switzerland)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Sanofi S.A. (France)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Merck & Co., Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Bayer AG (Germany)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Pfizer Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- GlaxoSmithKline plc (United Kingdom)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- AbbVie Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Johnson & Johnson Services, Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Celgene Corporation (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Bristol-Myers Squibb Company (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Mitsubishi Tanabe Pharma Corporation (Japan)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Biogen Idec International GmbH (Switzerland)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Genzyme Corporation (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- F. Hoffmann-La Roche Ltd (Switzerland)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Merck KGaA (Germany)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Mylan N.V. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Eisai Co., Ltd. (Japan)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Ipsen (France)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments

Global Multiple Sclerosis Drugs Market Size, Share, Growth Analysis, By Drug Type(Immunomodulatory, Immunosuppressant), By Route of Administration(Oral and Parenteral) - Industry Forecast 2023-2030

Description

Table of Contents

Table of Contents